- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 16-02-2026: Press Release
16-02-2026 | 04:00 pm
16-02-2026 | 04:00 pm
Lupin has signed a license and supply agreement with Spektus Pharma to commercialize the novel antidepressant DeslaFlex™ in Canada. This strategic move expands Lupin's CNS portfolio, offering new treatment options for Major Depressive Disorder and strengthening its market footprint.
No comments yet. Be the first to comment!